CardioInsight Technologies, Inc., a Cleveland, OH-based developer of non-invasive electrocardiographic mapping technology, has closed a $7.5m Series C financing.
Backers remained undisclosed.
The company intends to use the capital to accelerate clinical and commercial efforts related to its ECVUE™ advanced 3D cardiac mapping system, for which it recently obtained CE Mark certification.
In the coming months, CardioInsight will focus on securing its FDA regulatory clearance, demonstrating the value of the ECVUE System to improve the mapping of arrhythmias in routine clinical use, and proving its value in Cardiac Resynchronization Therapy (CRT).
Led by CEO Steve Arless, the company is commercializing a technology that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. CardioInsight has completed commercial installations at three centers in Europe, including St. Mary’s Hospital in London, England, the Kerckhoff Clinic in Bad Nauheim, Germany, and the Hopital Cardiologique du Haut-Leveque in Bordeaux, France.